Work

Challenges and Opportunities in Radioligand Therapy

Year: 2025

Type: article

Abstract: Radioligand therapy (RLT) is a recent term for long established nuclear medicine practices. Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include 68Ga-DOTATATE and 177Lu-DOTATATE, which target somatostatin receptor subtype 2 in neuroendocrine tumors, and 68Ga-PSMA-617 and 177Lu-PSMA-617, which target prostate cancer. There are several challenges and opportunities in the realization of precision medicine through RLT. RLT, weaponized in cancer management through advances in instrumentation and radiochemistry, is transforming the nuclear oncology landscape. Equitable access to these advanced tools remains a global consideration.

Source: Journal of Nuclear Medicine Technology

DOI: 10.2967/jnmt.125.270169

Authors: Geoffrey M. Currie, Dale L. Bailey

Institutions: Charles Sturt University, Baylor College of Medicine, The University of Sydney, Royal North Shore Hospital

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4416993143